RxDoctor Payments Data

Krishnaiah Rayasam, MD

Psychiatry · Corpus Christi, TXNPI 1831188903

Payments from drug & device makers

$3,379in general payments, 2019–2025

Across 143 payments — averaging $23.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$678
  • Alkermes, Inc.$500
  • Teva Pharmaceuticals USA, Inc.$471
  • Neurocrine Biosciences, Inc.$376
  • Sunovion Pharmaceuticals Inc.$330
  • Johnson & Johnson$304
  • plus $719 from 10 others

What the payments were for

  • Food & beverage$3,14993%
  • Education$2307%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,379 in reported general payments places this provider in the 80th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$3,974
Medicare patients
42
Services billed
100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate78$180,909
IngrezzaValbenazine Tosylate18$150,979
Invega TrinzaPaliperidone Palmitate16$97,197
FanaptIloperidone21$36,687
Abilify MaintenaAripiprazole13$34,727
CaplytaLumateperone Tosylate13$22,656
VraylarCariprazine Hcl14$22,474
Aripiprazole97$7,669
Quetiapine Fumarate325$5,992
Paliperidone ErPaliperidone37$5,885
Quetiapine Fumarate ErQuetiapine Fumarate60$4,840
Hydroxyzine Hcl217$4,391
Oxcarbazepine81$3,275
Chlorpromazine Hcl24$3,133
Desvenlafaxine Succinate ErDesvenlafaxine Succinate56$2,562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$304$278,10694 claims
Neurocrine Biosciences, Inc.Ingrezza$376$150,97918 claims
Vanda Pharmaceuticals Inc.Fanapt$32$36,68721 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$168$34,72713 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$176$22,65613 claims
AbbVieVraylar$99$22,47414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →